Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland

被引:3
|
作者
Thomann, Robert [1 ]
Zechmann, Stefan [2 ]
Alexander-David, Nicola
Jornayvaz, Francois R. [3 ]
机构
[1] Burgerspital, Solothurn, Switzerland
[2] Univ Zurich, Inst Primary Care, Zurich, Switzerland
[3] Hop Univ Geneve, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland
关键词
insulin glargine 300 U/mL; type; 2; diabetes; real-world; Switzerland; 100; U/ML; TYPE-2; PEOPLE;
D O I
10.2147/DMSO.S252667
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Insulin glargine 300 U/mL (Gla-300; Toujeo (R)) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100. Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5-10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety. Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p<0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p<0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population. Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.
引用
收藏
页码:2359 / 2365
页数:7
相关论文
共 50 条
  • [41] Treatment satisfaction in people with type 2 diabetes receiving basal insulin: results from real-world and randomised controlled studies with insulin glargine 300 U/ml
    Harris, S.
    Snoek, F. J.
    Meneghini, L. F.
    Lauand, F.
    Westerbacka, J.
    de Climens, A. Roborel
    Khunti, K.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S331 - S331
  • [42] Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naive Patients with Type 2 Diabetes Mellitus: DosInGlar Study
    Duque, Natalia
    Artime, Esther
    Romera, Irene
    Lebrec, Jeremie
    Diaz, Silvia
    Rubio, Miriam
    Sicras-Mainar, Antoni
    Carretero-Anibarro, Enrique
    Mundet, Xavier
    Gorgojo-Martinez, Juan J.
    Reviriego, Jesus
    [J]. ADVANCES IN THERAPY, 2021, 38 (07) : 3857 - 3871
  • [43] REAL-WORLD EFFECTIVENESS AND SAFETY OF INSULIN GLARGINE 300 U/ML (GLA-300) IN OLDER ADULTS (≥70 YEARS) WITH TYPE 2 DIABETES (T2D): ATOS STUDY SUBGROUP ANALYSIS
    Galstyan, G.
    Tirosh, A.
    Vargas-Uricoechea, H.
    Mabunay, M. A. N.
    Coudert, M.
    Pilorget, V.
    Khan, N.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A102 - A102
  • [44] Real-world effectiveness of antipsychotics
    Tuhonen, J.
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2016, 134 (05) : 371 - 373
  • [45] A real-world initiation into managed care
    Zupko, K
    [J]. HOSPITAL PRACTICE, 1997, 32 (05): : 202 - 204
  • [46] Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Older Adults (≥70 Years) with Type 2 Diabetes (T2DM): A Subgroup Analysis of the ATOS Study
    Galstyan, Gagik R.
    Tirosh, Amir
    Vargas-Uricoechea, Hernando
    Mabunay, Maria Aileen N.
    Coudert, Mathieu
    Pilorget, Valerie
    Khan, Niaz
    [J]. DIABETES, 2021, 70
  • [47] Glycemic Control With Insulin Glargine Plus Insulin Glulisine Versus Premixed Insulin Analogues in Real-World Practices: A Cost-Effectiveness Study With a Randomized Pragmatic Trial Design
    Levin, Philip A.
    Zhang, Quanwu
    Mersey, James H.
    Lee, Francis Y.
    Bromberger, Lee A.
    Bhushan, Madhu
    Bhushan, Rajat
    [J]. CLINICAL THERAPEUTICS, 2011, 33 (07) : 841 - 850
  • [48] Effectiveness of Insulin Glargine U300 Used as Part of Basal Bolus Therapy in People with T2DM-Toujeo 6 Months Real-World Data From Hungary
    Hidvegi, Tibor
    Stella, Peter
    [J]. DIABETES, 2018, 67
  • [49] Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus
    Freemantle, Nick
    Mauricio, Didac
    Giaccari, Andrea
    Bailey, Timothy
    Roussel, Ronan
    Franco, Denise
    Berthou, Baptiste
    Pilorget, Valerie
    Westerbacka, Jukka
    Bosnyak, Zsolt
    Bonnemaire, Mireille
    Cali, Anna M. G.
    Nguyen-Pascal, My-Lien
    Penfornis, Alfred
    Perez-Maraver, Manuel
    Seufert, Jochen
    Sullivan, Sean D.
    Wilding, John
    Wysham, Carol
    Davies, Melanie
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (04) : 571 - 581
  • [50] Real-World Safety and Effectiveness of Insulin Glargine 300 U/mL (Gla-300) in People with Type 2 Diabetes (T2DM) Who Fast during Ramadan: Regional Analysis of the ORION Study
    Hassanein, Mohamed
    Buyukbese, Mehmet A.
    Malek, Rachid, Sr.
    Pilorget, Valerie
    Naqvi, Mubarak
    Berthou, Baptiste
    Shaltout, Inass
    Sahay, Rakesh
    [J]. DIABETES, 2020, 69